Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lepor

Showing results (411-420 of 457) with videos related to

Pageof 46
Sort By:
Atherosclerosis|May 26, 2021
Regression in carotid plaque lipid content and neovasculature with PCSK9 inhibition: A time course studyNorman E Lepor, Jie Sun, Gador Canton, et al.
The International Journal of Cardiovascular Imaging|January 4, 2021
Serial magnetic resonance imaging detects a rapid reduction in plaque lipid content under PCSK9 inhibition with alirocumabJie Sun, Norman E Lepor, Gádor Cantón, et al.
Controlled Clinical Trials|April 12, 2003
Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trialOliver M Bautista, John W Kusek, Leroy M Nyberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2018
Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202James J Dignam, Daniel A Hamstra, Herbert Lepor, et al.
Advances in Radiation Oncology|March 11, 2026
Magnetic Resonance Imaging-Directed Stereotactic Body Radiation Therapy Microboost in Concert With Pelvic Nodal Irradiation for Prostate Cancer in the Higher-Risk Spectrum: ToxicityMina Musthafa, Markus Wells, Timothy Kearney, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 6, 2025
High-volume biopsy core involvement is not associated with failure after SBRT monotherapy for intermediate-risk prostate cancerJoshua C Hurwitz, Jonathan A Haas, Vianca F Santos, et al.
Journal of the National Cancer Institute|August 16, 2020
The Association of Veterans' PSA Screening Rates With Changes in USPSTF RecommendationsDaniel J Becker, Temitope Rude, Dawn Walter, et al.
JAMA|November 6, 2003
Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trialGregg W Stone, Peter A McCullough, James A Tumlin, et al.
Practical Radiation Oncology|November 20, 2023
Stereotactic Body Radiation Therapy for the Curative Treatment of Prostate Cancer in Ultralarge (≥100 cc) GlandsJoshua C Hurwitz, Jonathan Haas, Christopher Mendez, et al.
Cancer|June 29, 2021
Interaction between race and prostate cancer treatment benefit in the Veterans Health AdministrationTemitope Rude, Dawn Walter, Shannon Ciprut, et al.
Pageof 46

Showing results (411-420 of 457) with videos related to

Sort By:
Pageof 46
Atherosclerosis|May 26, 2021
Regression in carotid plaque lipid content and neovasculature with PCSK9 inhibition: A time course studyNorman E Lepor, Jie Sun, Gador Canton, et al.
The International Journal of Cardiovascular Imaging|January 4, 2021
Serial magnetic resonance imaging detects a rapid reduction in plaque lipid content under PCSK9 inhibition with alirocumabJie Sun, Norman E Lepor, Gádor Cantón, et al.
Controlled Clinical Trials|April 12, 2003
Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trialOliver M Bautista, John W Kusek, Leroy M Nyberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2018
Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202James J Dignam, Daniel A Hamstra, Herbert Lepor, et al.
Advances in Radiation Oncology|March 11, 2026
Magnetic Resonance Imaging-Directed Stereotactic Body Radiation Therapy Microboost in Concert With Pelvic Nodal Irradiation for Prostate Cancer in the Higher-Risk Spectrum: ToxicityMina Musthafa, Markus Wells, Timothy Kearney, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 6, 2025
High-volume biopsy core involvement is not associated with failure after SBRT monotherapy for intermediate-risk prostate cancerJoshua C Hurwitz, Jonathan A Haas, Vianca F Santos, et al.
Journal of the National Cancer Institute|August 16, 2020
The Association of Veterans' PSA Screening Rates With Changes in USPSTF RecommendationsDaniel J Becker, Temitope Rude, Dawn Walter, et al.
JAMA|November 6, 2003
Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trialGregg W Stone, Peter A McCullough, James A Tumlin, et al.
Practical Radiation Oncology|November 20, 2023
Stereotactic Body Radiation Therapy for the Curative Treatment of Prostate Cancer in Ultralarge (≥100 cc) GlandsJoshua C Hurwitz, Jonathan Haas, Christopher Mendez, et al.
Cancer|June 29, 2021
Interaction between race and prostate cancer treatment benefit in the Veterans Health AdministrationTemitope Rude, Dawn Walter, Shannon Ciprut, et al.
Pageof 46